Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials.

Mike Dennis, Jad Othman, Joanna Canham, Ian Thomas, Sean Johnson, Nick Telford, Beth Harrison, Jeyaprakash Ramachandran, James Cavenagh, Claire Arnold, Claus Marcher, Richard Kelly, Mhairi Copland, Alan Burnett, Richard Dillon, Nigel Russell

Blood (2025) 146 (Supplement 1): 3435.

https://doi.org/10.1182/blood-2025-3435

Published: 2025

Journal Articles

Detection of KMT2A fusion transcripts after induction chemotherapy is strongly predictive of outcome in KMT2A rearranged AML: Results of an international collaborative study

Blood (2025) 146 (Supplement 1): 346.

https://doi.org/10.1182/blood-2025-346

Published: 2025

Journal Articles

FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials

Blood (2025) 146 (Supplement 1): 345.

https://doi.org/10.1182/blood-2025-345

Published: 2025

Journal Articles

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Blood (2024) 144 (7): 714–728.

https://doi.org/10.1182/blood.2024024310

Published: 2024

Includes: Supplemental data

Journal Articles

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood (2024) 143 (19): 1931–1936.

https://doi.org/10.1182/blood.2023023096

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial

Nigel Russell, Alan Burnett, Robert Hills, Sophie Betteridge, Mike Dennis, Jelena Jovanovic, Richard Dillon, David Grimwade

Blood (2018) 132 (13): 1452–1454.

https://doi.org/10.1182/blood-2018-05-851824

Published: 2018

Journal Articles

Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia

Blood (2013) 121 (12): 2289–2300.

https://doi.org/10.1182/blood-2012-07-446120

Published: 2013

Includes: Supplemental data

Journal Articles

The Efficacy of the FLT3 Inhibitor Lestaurtinib in AML Depends on Adequate Plasma Inhibitory Activity (PIA), and Is Unaffected by Rising FLT Ligand Levels: An Update of the NCRI AML15 & 17 Trials

Steven Knapper, DM MRCP FRCPath, Paul White, PhD, Mark J. Levis, MD, PhD, Robert K Hills, MA, MSc, DPhil, Nigel H. Russell, MD, Alan Burnett, MD, ChB, FRCP, FRCPath, FMedSci

Blood (2011) 118 (21): 421.

https://doi.org/10.1182/blood.V118.21.421.421

Published: 2011

Journal Articles

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

Takashi Sato, Xiaochuan Yang, Steven Knapper, Paul White, B. Douglas Smith, Steven Galkin, Donald Small, Alan Burnett, Mark Levis

Blood (2011) 117 (12): 3286–3293.

https://doi.org/10.1182/blood-2010-01-266742

Published: 2011

Journal Articles

A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML

Andrew H Wei, MBBS, PhD, Sonali Sadawarte, John Catalano, MBBS, FRACP, FRCPA, Robert Hills, MA, MSc, DPhil, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, Alan Burnett, Andrew Spencer, MD

Blood (2010) 116 (21): 3299.

https://doi.org/10.1182/blood.V116.21.3299.3299

Published: 2010

Journal Articles

Younger Adult Acute Myeloid Leukemia (AML) Patients with IDH2-R140 Mutations Have a Significantly Better Prognosis Than Those with Either IDH2-R172 or IDH1 Mutations

Claire L Green, Catherine M Evans, Robert Hills, MA, MSc, DPhil, Lu Zhao, Alan Burnett, David C Linch, MD, Rosemary Gale, PhD

Blood (2010) 116 (21): 100.

https://doi.org/10.1182/blood.V116.21.100.100

Published: 2010

Journal Articles

Analysis of the Interaction of Induction Regimens with P-Glycoprotein Expression In Patients with Acute Myeloid Leukaemia: Results From the MRC AML15 Trial

Monica Pallis, PhD, Paul White, PhD, Robert Hills, MA, MSc, DPhil, Martin Grundy, BSc, Nigel H. Russell, MD, Alan Burnett

Blood (2010) 116 (21): 2724.

https://doi.org/10.1182/blood.V116.21.2724.2724

Published: 2010

Journal Articles

Prognostic Significance of Cryptic Genomic Aberrations In AML with Normal Karyotype

Azim Mohamedali, Robert Hills, MA, MSc, DPhil, Erick E Nasser, Atiyeh Abdallah, Austin G Kulasekararaj, Amanda Gilkes, Nicholas Lea, Alan Burnett, Ghulam J. Mufti, DM, FRCP, FRCPath

Blood (2010) 116 (21): 2729.

https://doi.org/10.1182/blood.V116.21.2729.2729

Published: 2010

Journal Articles

PDK1 Overexpression In Acute Myeloid Leukemia; Clinical Significance and Potential as a Therapeutic Target

Joanna Zabkiewicz, PhD, Lorna Pearn, Robert Hills, MA, MSc, DPhil, Rhys, Gareth Morgan, BSc, Alan Burnett, MD, Alex Tonks, PhD, Richard L Darley, PhD

Blood (2010) 116 (21): 2162.

https://doi.org/10.1182/blood.V116.21.2162.2162

Published: 2010

Journal Articles

Detection of Immunophenotypic Residual Disease After Induction Therapy Is An Independent Prognostic Factor for Duration of Remission In Older AML Patients Treated Intensively

Sylvie Freeman, Robert Hills, MA, MSc, DPhil, Paul Virgo, Steve Couzens, Mark W Lowdell, BSc, MSc, PhD, FRCPath, Christopher J McNamara, Paul White, Alan Burnett

Blood (2010) 116 (21): 2714.

https://doi.org/10.1182/blood.V116.21.2714.2714

Published: 2010

Journal Articles

Over-Expression of CD200 In Acute Myeloid Leukemia Mediates the Expansion of Regulatory T-Lymphocytes and Directly Inhibits Natural Killer Cell Tumor Immunity

Steven J Coles, PhD, Stephen Man, PhD, Robert Hills, MA, MSc, DPhil, Eddie CY Wang, PhD, Alan Burnett, MD, Richard L Darley, PhD, Alex Tonks, PhD

Blood (2010) 116 (21): 491.

https://doi.org/10.1182/blood.V116.21.491.491

Published: 2010

Journal Articles

A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls

Kate Stringaris, MD, MRCP, FRCPath, A. John Barrett, MD, Robert Hills, MA, MSc, DPhil, David C Linch, MD, FMedSci, Rosemary Gale, PhD, Christopher Allen, Paula Garland, MBBS, MRCP, Ruhena Sargent, Hugues de Lavallade, Abdullah Alsuliman, Ahmad Khoder, Dr, Ian H Gabriel, Dr, Takuya Sekine, Alan Burnett, Katayoun Rezvani, Jane F. Apperley

Blood (2010) 116 (21): 1697.

https://doi.org/10.1182/blood.V116.21.1697.1697

Published: 2010

Journal Articles

Distinct Regulation of β- and γ-Catenin throughout Hematopoietic Development Contrasts with Their Cooperative Roles In Acute Myeloid Leukemia.

Rhys Gareth Morgan, BSc, Lorna Pearn, Kate Liddiard, PhD, Robert Hills, MA, MSc, DPhil, Alan Burnett, MD, Alex Tonks, PhD, Richard L Darley, PhD

Blood (2010) 116 (21): 1573.

https://doi.org/10.1182/blood.V116.21.1573.1573

Published: 2010

Journal Articles

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

Alan Burnett, Robert Hills, MA, MSc, DPhil, Ann Elizabeth Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, FRCP, FRCPath, William J. Kell, MD, MB, Keith Wheatley, John Yin, MD, Mary Frances McMullin, MD, Helen Dignum, David Bowen, Nigel H. Russell, MD

Blood (2010) 116 (21): 18.

https://doi.org/10.1182/blood.V116.21.18.18

Published: 2010

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials.

Detection of KMT2A fusion transcripts after induction chemotherapy is strongly predictive of outcome in KMT2A rearranged AML: Results of an international collaborative study

FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial

Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia

The Efficacy of the FLT3 Inhibitor Lestaurtinib in AML Depends on Adequate Plasma Inhibitory Activity (PIA), and Is Unaffected by Rising FLT Ligand Levels: An Update of the NCRI AML15 & 17 Trials

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML

Younger Adult Acute Myeloid Leukemia (AML) Patients with IDH2-R140 Mutations Have a Significantly Better Prognosis Than Those with Either IDH2-R172 or IDH1 Mutations

Analysis of the Interaction of Induction Regimens with P-Glycoprotein Expression In Patients with Acute Myeloid Leukaemia: Results From the MRC AML15 Trial

Prognostic Significance of Cryptic Genomic Aberrations In AML with Normal Karyotype

PDK1 Overexpression In Acute Myeloid Leukemia; Clinical Significance and Potential as a Therapeutic Target

Detection of Immunophenotypic Residual Disease After Induction Therapy Is An Independent Prognostic Factor for Duration of Remission In Older AML Patients Treated Intensively

Over-Expression of CD200 In Acute Myeloid Leukemia Mediates the Expansion of Regulatory T-Lymphocytes and Directly Inhibits Natural Killer Cell Tumor Immunity

A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls

Distinct Regulation of β- and γ-Catenin throughout Hematopoietic Development Contrasts with Their Cooperative Roles In Acute Myeloid Leukemia.

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only